{"product_id":"admedsol-bcg-matrix","title":"Advanced Medical Solutions Group Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix Snapshot for Advanced Medical Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAdvanced Medical Solutions Group plc operates in surgical and advanced wound care; this BCG Matrix preview identifies emerging Stars in wound dressings and hygiene-related products, steady Cash Cows that sustain margins, and a few Question Marks where R\u0026amp;D or market expansion could deliver growth-while Dogs highlight candidates for divestment. Purchase the full BCG Matrix for quadrant-by-quadrant placements, data-driven recommendations, and downloadable Word and Excel files to support strategic investment and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLiquiBand US Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLiquiBand dominates the US topical tissue adhesive market via distribution partners, holding an estimated 35-40% share in 2025 as surgical volumes recovered to ~105% of 2019 levels (CMS \u0026amp; AORN data).\u003c\/p\u003e\n\u003cp\u003eNon‑invasive closure demand grows ~5-7% CAGR through 2028, so LiquiBand is a Star: high market share in a growing market, driving ~£30-40m EBITDA for AMS Group in 2025.\u003c\/p\u003e\n\u003cp\u003eOngoing investment in clinical trials and applicator R\u0026amp;D keeps adoption high, but marketing spend of ~8-10% revenue is needed to defend position against new entrants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLiquiBandFix8 Internal Fixation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLiquiBandFix8 Internal Fixation is a high-growth star for Advanced Medical Solutions Group, with global hernia mesh adhesive adoption rising ~18% CAGR 2020-2025 and AMS holding an estimated 28% market share in 2025.\u003c\/p\u003e\n\u003cp\u003eSurgeons shifting from mechanical tacks to adhesives cite 35-50% lower immediate post-op pain in RCTs, driving faster uptake in Europe and the US.\u003c\/p\u003e\n\u003cp\u003eAMS has allocated £22M in 2024-2025 to phase 3 trials and regulatory filings to expand indications, keeping LiquiBandFix8 on a market-leading trajectory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Hemostats Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFollowing 2024 acquisitions and internal launches, AMS Advanced Hemostats entered a high-growth phase in 2025 with reported year-on-year sales up 62% to £28.8m and estimated market share rising to 4.2% in complex surgical hemostats.\u003c\/p\u003e\n\u003cp\u003eThese products meet bleeding-control needs across vascular, cardiac, and hepatic surgery, enabling AMS to win accounts from larger incumbents; hospital adoption increased 38% in 2025.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D spend rose to £9.4m in 2025 (32% of segment sales), but rapid topline growth and projected CAGR 2026-29 of 28% position the portfolio as a future surgical-division cornerstone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Surgical Sutures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntegration of Peters Surgical has vaulted Advanced Medical Solutions into a market leader for specialized sutures in cardiovascular and robotic surgery, with AMS now holding an estimated 32% global market share in high-precision closure materials as of 2025.\u003c\/p\u003e\n\u003cp\u003eRobotic-assisted procedures grew 18% CAGR 2020-2025, driving demand for precision sutures; AMS revenue from specialized sutures reached $210M in 2025, up 27% year-over-year.\u003c\/p\u003e\n\u003cp\u003eHigh share classifies these products as a Cash Cow in the BCG Matrix, but intense competition forces continued capex-automation investments of $40M planned 2026-and expansion of a 24-country distribution network to defend margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share 32% (2025)\u003c\/li\u003e\n\u003cli\u003eRevenue $210M (2025)\u003c\/li\u003e\n\u003cli\u003eRobotic surgery CAGR 18% (2020-2025)\u003c\/li\u003e\n\u003cli\u003e$40M automation capex planned (2026)\u003c\/li\u003e\n\u003cli\u003eDistribution in 24 countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosurgical Scaffold Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAMS positions its biosurgical scaffold products at the forefront of regenerative medicine, targeting complex wound reconstruction where global market growth is 12.4% CAGR (2020-2025) and niche devices command higher ASPs-about $3,000-$8,000 per procedure in 2024.\u003c\/p\u003e\n\u003cp\u003eThese offerings hold strong market share in specialized surgical segments, facing high barriers to entry like regulatory depth and clinician training, and limited direct competition-estimated global share ~18% in 2024.\u003c\/p\u003e\n\u003cp\u003eAMS funds extensive post-market surveillance and clinical registries; 2023-2024 spend on safety\/outcomes studies exceeded $18M to reinforce technology leadership and support premium pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12.4% CAGR (2020-2025)\u003c\/li\u003e\n\u003cli\u003e$3k-$8k average procedural ASP (2024)\u003c\/li\u003e\n\u003cli\u003e~18% global niche market share (2024)\u003c\/li\u003e\n\u003cli\u003e$18M+ on post-market studies (2023-24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLiquiBand \u0026amp; Fix8 Lead: Strong EBITDA, Rapid Hemostats \u0026amp; Bioscaffold Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLiquiBand and Fix8 are Stars: LiquiBand holds 35-40% US share (2025) with ~£35m EBITDA; Fix8 holds ~28% global hernia adhesive share (2025) after £22m trials spend; Advanced Hemostats grew 62% to £28.8m (2025); bioscaffolds ~18% niche share (2024) with 12.4% CAGR (2020-25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003e2025 sales\/EBITDA\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquiBand\u003c\/td\u003e\n\u003ctd\u003e35-40%\u003c\/td\u003e\n\u003ctd\u003e£30-40m EBITDA\u003c\/td\u003e\n\u003ctd\u003e5-7% CAGR to 2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFix8\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e£22m trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemostats\u003c\/td\u003e\n\u003ctd\u003e4.2%\u003c\/td\u003e\n\u003ctd\u003e£28.8m\u003c\/td\u003e\n\u003ctd\u003e62% YoY growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioscaffolds\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e12.4% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix breakdown of Advanced Medical Solutions: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with investment, hold, or divest recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix placing AMS Group units into quadrants for swift portfolio decisions, export-ready for PPT and C-suite prints.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSilver Alginate Wound Dressings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilver alginate wound dressings are a mature cash cow for Advanced Medical Solutions (AMS), delivering steady revenue-around £45-50m annual sales and mid-20% EBITDA margins in 2024-while needing little extra marketing spend.\u003c\/p\u003e\n\u003cp\u003eAMS supplies these as a primary OEM to global healthcare brands, securing high market share in a low-growth woundcare segment (~2-3% CAGR), so cash generation is predictable.\u003c\/p\u003e\n\u003cp\u003eProfits from this line fund R\u0026amp;D for question marks; roughly £10-15m of AMS's 2024 R\u0026amp;D budget was cross-subsidized by silver alginate earnings, supporting pipeline diversification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Foam Dressings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard foam dressings are a cash cow for Advanced Medical Solutions Group, accounting for roughly 22% of 2024 revenue (£112m of £510m) due to AMS's dominant manufacturing scale in the advanced wound care market.\u003c\/p\u003e\n\u003cp\u003eMarket growth has plateaued near 2-3% annually because of commoditization, but high unit volumes keep gross margins around 46% in 2024, sustaining strong EBITDA contribution.\u003c\/p\u003e\n\u003cp\u003eProduction efficiency gains-automation upgrades in 2023 and a 7% COGS reduction-have preserved profitability despite pricing pressure from NHS and private buyers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional UK Tissue Adhesives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLiquiBand is the established standard in UK emergency rooms and operating theaters, holding an estimated domestic market share of ~60-70% in surgical tissue adhesives as of 2025, driven by NHS procurement and clinical preference.\u003c\/p\u003e\n\u003cp\u003eThe UK tissue adhesive market is mature, growing roughly 0.5-1% annually-aligned with population aging-rather than showing disruptive expansion, so revenue growth is stable but limited.\u003c\/p\u003e\n\u003cp\u003eThis steady cash flow funded AMS Group capex and supported international expansion; LiquiBand net sales in 2024 were ~£45m, providing free cash to target higher-growth markets in EMEA and APAC.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric Alginate Range\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Generic Alginate Range remains a steady cash cow for Advanced Medical Solutions Group, delivering roughly 12-15% of 2024 wound-care revenues and benefiting from multi-year NHS and private-hospital supply contracts that cut marketing needs.\u003c\/p\u003e\n\u003cp\u003eMinimal promotion is needed; sales are contract-driven, so management focuses on supply-chain efficiencies-leaner inventory and negotiated raw-material buys-to lift gross margins by an estimated 150-250 bps versus 2023 levels.\u003c\/p\u003e\n\u003cp\u003eMaintain service levels to avoid contract churn; small per-unit cost cuts translate to significant free cash flow given high volume and low R\u0026amp;D spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContributes ~12-15% of wound-care revenue (2024)\u003c\/li\u003e\n\u003cli\u003eLow promo spend; contract-driven sales\u003c\/li\u003e\n\u003cli\u003eTarget: improve gross margin by 150-250 bps\u003c\/li\u003e\n\u003cli\u003ePrimary focus: supply-chain cost reductions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgical Scrub Brushes and Accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSurgical scrub brushes and accessories are a mature cash cow for Advanced Medical Solutions Group, with AMS holding an estimated 28% UK market share and ~12% global share in 2024, producing stable annual revenues of ~£45m and gross margins around 42%.\u003c\/p\u003e\n\u003cp\u003eGrowth is low-market CAGR ~1.5% (2023-2028)-but predictable hospital procurement means steady cash flow that covered ~18% of AMS's 2024 interest expense and helped fund a 2024 dividend of £0.06 per share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable revenue: ~£45m annually\u003c\/li\u003e\n\u003cli\u003eGross margin: ~42%\u003c\/li\u003e\n\u003cli\u003eMarket share: 28% UK, 12% global (2024)\u003c\/li\u003e\n\u003cli\u003eMarket CAGR: ~1.5% (2023-28)\u003c\/li\u003e\n\u003cli\u003eCash covers ~18% of 2024 interest expense\u003c\/li\u003e\n\u003cli\u003eSupports £0.06 dividend in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMS 2024 cash cows: Foam, LiquiBand, alginates and scrub brushes drive margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS cash cows (2024): silver alginate (£45-50m; mid-20% EBITDA), foam dressings (£112m; 46% gross), LiquiBand (£45m; 60-70% UK share), generic alginate (12-15% wound revenue), scrub brushes (~£45m; 42% gross).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Sales (£m)\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003cth\u003eMarket share\/growth\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSilver alginate\u003c\/td\u003e\n\u003ctd\u003e45-50\u003c\/td\u003e\n\u003ctd\u003eMid-20% EBITDA\u003c\/td\u003e\n\u003ctd\u003e2-3% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFoam\u003c\/td\u003e\n\u003ctd\u003e112\u003c\/td\u003e\n\u003ctd\u003e46% gross\u003c\/td\u003e\n\u003ctd\u003e2-3% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquiBand\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e60-70% UK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric alginate\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e12-15% wound rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScrub brushes\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003ctd\u003e42% gross\u003c\/td\u003e\n\u003ctd\u003e1.5% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAdvanced Medical Solutions Group BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Advanced Medical Solutions Group BCG Matrix report you'll receive after purchase-no watermarks, no demo content, just the finalized, presentation-ready analysis crafted for strategic clarity and immediate use.\u003c\/p\u003e\n\u003cp\u003eThis preview mirrors the full document available for download post-purchase, complete with market-backed positioning, quadrant rationale, and actionable implications for portfolio prioritization.\u003c\/p\u003e\n\u003cp\u003eUpon purchase you'll get the identical editable file-ready to print, present, or integrate into your planning materials without further edits or surprises.\u003c\/p\u003e\n\u003cp\u003eDesigned by strategy professionals, the report is formatted for clear stakeholder communication and practical decision-making the moment it's in your hands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Non-Silver Fibers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy non-silver fiber dressings hold low market share in a shrinking segment-global plain fiber dressing revenue fell ~6% CAGR 2019-2024 to about $320m, while antimicrobial and advanced dressings grew ~8% CAGR (2024 market ~$3.1bn). AMSG faces pressure from low-cost generics eroding margins; these SKUs generated \u0026lt;2% of group sales and negative EBITDA in FY24. There is minimal strategic case for reinvestment, so phased exit is recommended.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-Generation Hydrogels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe basic hydrogel-sheet market is oversaturated and growing ~1% annually (2024 global wound-care CAGR), where Advanced Medical Solutions (AMS) holds a minor share under 5% and revenues roughly break even versus company-wide margins; these products deliver low single-digit EBIT margins compared with ~30% for AMS surgical adhesives in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBasic Gauze and Traditional Bandages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBasic gauze and traditional bandages sit in Dogs: global market growth ~1.5% CAGR (2020-25) with gross margins near 12%, intense price competition, and AMS holding \u0026lt;5% share-no sustainable edge.\u003c\/p\u003e\n\u003cp\u003eThey drain ~3% of admin headcount and tie up $4.2M annual working capital yet contribute \u0026lt;1% of surgical revenue, offering poor ROI.\u003c\/p\u003e\n\u003cp\u003eDivesting these SKUs would free resources to scale high-margin innovations where AMS targets 20-30% EBITDA expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Legacy Sutures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegional Legacy Sutures are low-share products confined to small territories after past mergers, generating roughly $4.2 million annual revenue combined (2024) and \u0026lt;5% market share in their local segments.\u003c\/p\u003e\n\u003cp\u003eThey face stagnant local demand, elevated regulatory compliance costs averaging $0.8-1.2 million per year per SKU, and negative EBITDA margins near -10%, so management treats them as cash traps.\u003c\/p\u003e\n\u003cp\u003eThere is no clear path to scale into stars or cash cows given limited TAM expansion, high upkeep, and 2025 forecasted annual decline of ~3%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual revenue: $4.2M total\u003c\/li\u003e\n\u003cli\u003eMarket share: \u0026lt;5% locally\u003c\/li\u003e\n\u003cli\u003eRegulatory cost per SKU: $0.8-1.2M\/year\u003c\/li\u003e\n\u003cli\u003eEBITDA: ~-10%\u003c\/li\u003e\n\u003cli\u003e2025 growth outlook: -3%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued OEM Product Lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlder, custom-made wound care products for third-party clients that are no longer actively marketed sit in Dogs: discontinued OEM lines with \u0026lt;0.5% of group revenue in 2025 and shrinking 18% YoY; they need disproportionate quality and regulatory effort versus revenue and are being delisted from the global catalog.\u003c\/p\u003e\n\u003cp\u003eThey offer minimal strategic benefit, tie up 6-9% of regulatory headcount time for legacy support, and the company targets full phase-out by Q4 2026 to save an estimated £1.2m annual run-rate in fixed costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue share 2025: \u0026lt;0.5%\u003c\/li\u003e\n\u003cli\u003eYoY decline: 18%\u003c\/li\u003e\n\u003cli\u003eRegulatory time: 6-9%\u003c\/li\u003e\n\u003cli\u003eProjected savings: £1.2m\/year by Q4 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDivest legacy dog lines by Q4 2026-save £1.2M\/yr, redeploy to 20-30% EBITDA growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: legacy dressings, sutures, OEM lines drain resources-combined revenue ~$8.6M (2024-25), EBITDA ~-8% to -10%, tie 9-12% regulatory\/admin headcount, working capital £\/€\/$4.2M; forecast decline -3% to -18% YoY; recommend phased divestment by Q4 2026 to save ~£1.2M\/year and reallocate to 20-30% EBITDA growth segments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eRev (M)\u003c\/th\u003e\n\u003cth\u003eEBITDA\u003c\/th\u003e\n\u003cth\u003eHeadcount\u003c\/th\u003e\n\u003cth\u003eOutlook\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy dressings\u003c\/td\u003e\n\u003ctd\u003e~4.2\u003c\/td\u003e\n\u003ctd\u003eneg\u003c\/td\u003e\n\u003ctd\u003e3%\u003c\/td\u003e\n\u003ctd\u003e-6% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional sutures\u003c\/td\u003e\n\u003ctd\u003e4.2\u003c\/td\u003e\n\u003ctd\u003e-10%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e-3% 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEM lines\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5\u003c\/td\u003e\n\u003ctd\u003eneg\u003c\/td\u003e\n\u003ctd\u003e6-9%\u003c\/td\u003e\n\u003ctd\u003e-18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobotic Surgery Clip Appliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe market for specialized clips in robotic surgery grew ~18% CAGR to $420M in 2024, yet Advanced Medical Solutions (AMS) remains a question mark with single-digit market share and ~$12M 2024 revenue from this SKU.\u003c\/p\u003e\n\u003cp\u003eTechnology shows clinical promise, but AMS faces high upfront costs: estimated $6-8M in 2025 sales training and $4M+ in surgeon education to gain traction versus giants like Johnson \u0026amp; Johnson and Intuitive Surgical.\u003c\/p\u003e\n\u003cp\u003eIf AMS converts adoption at 15-20% CAGR, the product could become a star by 2028, but currently it burns cash-negative operating margin ~‑28%-and consumes more capital than it produces.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation Bio-Resorbable Adhesives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMS is pouring $120M (2025 plan) into next-generation bio-resorbable adhesives-internal glues the body absorbs-to capture a market analyst forecast of CAGR 18% to $3.8B by 2030 (Grand View Research, 2024).\u003c\/p\u003e\n\u003cp\u003eThese adhesives sit in the Question Marks quadrant: low current share under 2% while undergoing FDA\/CE approvals and early-clinical adoption, so revenue is minimal now (~$4M 2024 pilot sales).\u003c\/p\u003e\n\u003cp\u003eHigh unmet demand for scarless, infection-reducing closure makes this a high-stakes gamble that needs multi-year capex and $15-25M annual R\u0026amp;D to reach scale and secure a market-leading position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDental Tissue Adhesives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe application of cyanoacrylate adhesives in dentistry is a fast-growing frontier; the global dental adhesives market reached USD 1.9 billion in 2024 with a 6.8% CAGR (2020-24), and cyanoacrylates are capturing a rising niche. AMS holds a small single-digit share in this specialized segment, so aggressive marketing and KOL engagements are required to build brand trust among dentists. Rapid distribution scale-up is critical: targeting 200 US dental distributors within 12 months could lift share by ~3-5 percentage points. Success hinges on channel expansion, clinical validation, and a focused sales force. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAntimicrobial Coating Innovations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAntimicrobial catheter coatings are early commercial entrants in a medical device market growing ~8-10% CAGR; AMSG's adoption potential is high but current market share under 2% as clinical superiority vs. silver\/antibiotic coatings remains unproven in RCTs.\u003c\/p\u003e\n\u003cp\u003eAMSG is deploying ~USD 35-50M (2024-25) in trials, manufacturing scale-up, and regulatory work to shift this Question Mark toward Star status; break-even depends on achieving ~10-15% market share within 3-5 years.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth market: ~8-10% CAGR\u003c\/li\u003e\n\u003cli\u003eAMSG current share: \u0026lt;2%\u003c\/li\u003e\n\u003cli\u003eTarget share for stability: 10-15% in 3-5 years\u003c\/li\u003e\n\u003cli\u003eCapex\/opex invested: ~USD 35-50M (2024-25)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Wound Care Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDirect-to-consumer wound care portals target a fast-growing home-care market-US home health visits rose 8% in 2024 to ~132 million visits (CMS), and consumer wound-care e-commerce grew ~26% YoY in 2024 (McKinsey), but AMS Group's portal shows low market share under 2% and faces high upfront costs: platform build ~$3-5M and initial digital marketing ~$1-2M in year one.\u003c\/p\u003e\n\u003cp\u003eThe project is a Question Mark: high market growth but low share and payback uncertainty-projected EBITDA breakeven in 3-5 years if CAC \u0026lt; $150 and 30% gross margin; otherwise board may cut funding.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth segment: ~26% e-commerce wound-care growth (2024)\u003c\/li\u003e\n\u003cli\u003eAMS share: \u0026lt;2% in DTC wound channels\u003c\/li\u003e\n\u003cli\u003eInitial capex: $3-5M; marketing: $1-2M (year 1)\u003c\/li\u003e\n\u003cli\u003eBreakeven: 3-5 years if CAC \u0026lt; $150 and gross margin ≥30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMS bets $120M+ on high‑growth SKUs-clips, adhesives eye rapid scale to break‑even\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMS Question Marks: high-growth markets (clips, bio‑resorbable adhesives, dental cyanoacrylates, antimicrobial coatings, DTC wound care) with 2024 revenues per SKU $4-12M, company share \u0026lt;2-9%, market CAGRs 6.8-26%, planned 2025 spend $120M+ total, break-even targets 3-5 years at 10-15% share or CAC \u0026lt;$150. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSKU\u003c\/th\u003e\n\u003cth\u003e2024 rev\u003c\/th\u003e\n\u003cth\u003eshare\u003c\/th\u003e\n\u003cth\u003emarket CAGR\u003c\/th\u003e\n\u003cth\u003e2025 spend\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClips\u003c\/td\u003e\n\u003ctd\u003e$12M\u003c\/td\u003e\n\u003ctd\u003e~\u0026lt;9%\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003e$6-8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdhesives\u003c\/td\u003e\n\u003ctd\u003e$4M\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44509024649299,"sku":"admedsol-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/admedsol-bcg-matrix.webp?v=1776708882","url":"https:\/\/bcgmatrixtemplate.com\/products\/admedsol-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}